Optomed Plc (OPTOMED.XHEL) Quality Score
Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Valuation
Growth
Negative earnings, no valuation support
Negative FCF, no valuation support
2–5% CAGR, growing but slowly
FCF negative, burning cash after capex
Business Quality & Capital Allocation
Heavy dilution above 5%
Contracted >2pp, margin pressure
Net cash position, no leverage concern
Below 8%, may not cover cost of capital
Optomed (OPTOMED.XHEL) quality: score, margins and returns
Optomed (OPTOMED.XHEL) scores 18/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 6 metrics each scored 0 to 100, on -36.9% operating margins and -17.6% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.
Frequently asked
Is Optomed (OPTOMED.XHEL) a high-quality business?+
Optomed scores 18 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -36.9% operating margin and a -17.6% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does Optomed's quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from OPTOMED.XHEL's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Optomed scores well and where it falls behind.
What is Optomed's return on invested capital (ROIC)?+
Optomed earns about -17.6% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to OPTOMED.XHEL's margins and growth on this scorecard to judge durability.
How profitable is Optomed?+
Optomed runs an operating margin of about -36.9% and a net margin of about -37.5%. Revenue has grown at roughly 3.6% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.
Related stocks: Health Information Services
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.